These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18874021)

  • 1. The effect of anti-reticular cytotoxic serum; observations on cases of Hodgkin's disease.
    ABERNETHY JW; HARRELL GT
    N C Med J; 1948 Jul; 9(7):341-50. PubMed ID: 18874021
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic use of anti-reticular cytotoxic serum in Hodgkin's disease.
    SKAPIER J
    Cancer Res; 1947 Jun; 7(6):369-71. PubMed ID: 18909138
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of cytotoxic Hodgkin's serum on LIF activity of T- and B-lymphocytes].
    Chisesi T; Giacobbo M; Capnist T
    Boll Ist Sieroter Milan; 1978 Sep; 57(4):428-33. PubMed ID: 310684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaction of immune complexes with Hodgkin's disease tissue cultures: radioimmune assay and immunoferritin electron microscopy.
    Long JC; Dvorak AM; Quay SC; Stamatos C; Chi SY
    J Natl Cancer Inst; 1979 Apr; 62(4):787-97. PubMed ID: 372654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Utilization of "anti-serum specific" immune serums for the study of abnormal circulating proteins (in acute leukemia, Hodgkin's disease and disseminated lupus erythematosus)].
    CAETANO JA; da COSTA S; SOARES AD; da SILVA J
    Gaz Med Port; 1960; 13():575-82. PubMed ID: 13689743
    [No Abstract]   [Full Text] [Related]  

  • 6. Hodgkin's disease, with terminal generalized tuberculosis.
    CAYER D; LAWSON RB
    N C Med J; 1947 Jan; 8(1):42-6. PubMed ID: 20280047
    [No Abstract]   [Full Text] [Related]  

  • 7. A critical evaluation of anti-reticular cytotoxic serum (ACS).
    GARDNER TS; SPEAKER DM
    Tex Rep Biol Med; 1951; 9(3):448-90. PubMed ID: 14866865
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-reticular cytotoxic serum (ACS).
    WRIGHT HP
    Can Med Assoc J; 1947 Jan; 56(1):84. PubMed ID: 20277533
    [No Abstract]   [Full Text] [Related]  

  • 9. Hodgkin's disease coexistent with plasma cell dyscrasia.
    Zarate-Osorno A; Medeiros LJ; Jaffe ES
    Arch Pathol Lab Med; 1992 Sep; 116(9):969-72. PubMed ID: 1524465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-reticular cytotoxic serum in chronic skin ulcers.
    MASHKILLEISON LN
    Am Rev Sov Med; 1946 Jun; 3():443-7. PubMed ID: 20985833
    [No Abstract]   [Full Text] [Related]  

  • 11. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
    Pappas A; Pees H; Girmann G
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antireticular cytotoxic serum in the treatment of arthritis; observations on 44 cases.
    SOLOMON WM; STECHER RM
    J Lab Clin Med; 1948 Jun; 33(6):768-71. PubMed ID: 18865755
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bogomolets Serum; indications, contraindications and tests prior to the use of cytotoxic anti-reticular serum in surgical conditions].
    COLIN C
    Rev Mex Cienc Med Bio; 1949 Jan; 7(43):1-10. PubMed ID: 18112841
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-reticular cytotoxic or Bogomoletz' serum].
    COSTA BERTANI G
    Rev Asoc Med Argent; 1950 Sep 15-30; 64(685-686):425-30. PubMed ID: 14808726
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of antireticular cytotoxic serum upon the respiration of bone marrow suspensions.
    COHEN AL; RUNJAVAC M; STRAUS R
    Tex Rep Biol Med; 1947; 5(3):341-6. PubMed ID: 20269737
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bogomoletz's serum; Cytotoxic anti-reticular serum (S.C.A.)].
    WEBER-BAULER L
    Med Hyg (Geneve); 1946 Dec; 4(88):1. PubMed ID: 20246621
    [No Abstract]   [Full Text] [Related]  

  • 17. [Circulating immune complexes in the serum in Hodgkin's disease].
    Nikolić V; Zivanović L; Banićević B; Milosević-Jovcić N
    Bilt Hematol Transfuz; 1980; 8(1):19-27. PubMed ID: 7337679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low grade non-Hodgkin's lymphoma after combined therapy for Hodgkin's disease].
    Raya Sánchez JM; González Brito G; Hernández Nieto L; Brito Barroso ML; Alvarez Argüelles H; Jorge Hernández JA; Martín Herrera A
    Sangre (Barc); 1994 Dec; 39(6):461-4. PubMed ID: 7855699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between serum factors and T lymphocytes in Hodgkin's disease. Use as a diagnostic test.
    Fuks Z; Strober S; Kaplan HS
    N Engl J Med; 1976 Dec; 295(23):1273-8. PubMed ID: 185517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
    Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
    J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.